Current state and future directions of neurochemical biomarkers for Alzheimer's disease

被引：66

作者：

de Jong, Dankille

Kremer, Berry P. H.

Olde Rikkert, Marcel G. M.

Verbeek, Marcel M.

机构：

[1] Radboud Univ Nijmegen Med Ctr, Dept Neurol, NL-6500 Nijmegen, Netherlands

[2] Radboud Univ Nijmegen Med Ctr, Alzheimer Ctr Nijmegen, Nijmegen, Netherlands

[3] Radboud Univ Nijmegen Med Ctr, Dept Geriatr Med, Nijmegen, Netherlands

[4] Radboud Univ Nijmegen Med Ctr, Lab Pediat & Neurol, Nijmegen, Netherlands

来源：

CLINICAL CHEMISTRY AND LABORATORY MEDICINE | 2007年 / 45卷 / 11期

关键词：

Alzheimer's disease; amyloid beta protein; biological markers; cerebrospinal fluid; tau proteins;

D O I：

10.1515/CCLM.2007.320

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

In this comprehensive review, we summarize the current state-of-the-art of neurochemical biomarkers for Alzheimer's disease. Predominantly, these biomarkers comprise cerebrospinal fluid biomarkers directly related to the pathophysiology of this disorder (such as amyloid beta protein, tau protein). We particularly pay attention to the innovations in this area that have been made in technological aspects during the past 5 years (e.g., multiplex analysis of biomarkers, proteomics), to the discovery of novel, potential biomarkers (e.g., amyloid beta oligomers, isoprostanes), and to the extension of this research towards identification of biomarkers in plasma.

引用

页码：1421 / 1434

页数：14

共 167 条

[41]

Davidsson P, 2001, PROTEOMICS, V1, P444

[42] CSF neurofilament proteins in the differential diagnosis of dementia [J].